Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection

• DOI: 10.1111/jgh.14874
• Publication Date: 2019-10-14T15:29:42Z
• Authors: Hidenori Toyoda; Masanori Atsukawa; Tsunamasa Watanabe; Makoto Nakamuta; Haruki Uojima; Akito Nozaki; Koichi Takaguchi; Shinichi Fujioka; Etsuko Iio; Toshihide Shima; Takehiro Akahane; Shinya Fukunishi; Toru Asano; Kojiro Michitaka; Kunihiko Tsuji; Hiroshi Abe; Shigeru Mikami; Hironao Okubo; Tomomi Okubo; Noritomo Shimada; Toru Ishikawa; Akio Moriya; Joji Tani; Asahiro Morishita; Chikara Ogawa; Yoshihiko Tachi; Hiroki Ikeda; Naoki Yamashita; Satoshi Yasuda; Makoto Chuma; Akemi Tsutsui; Atsushi Hiraoka; Tadashi Ikegami; Takuya Genda; Akihito Tsubota; Tsutomu Masaki; Yasuhito Tanaka; Katsuhiko Iwakiri; Takashi Kumada
• Keywords: Tolerability; Regimen; Hepatitis C

Abstract Background In clinical trials, a pangenotype direct‐acting antiviral (DAA) regimen consisting of glecaprevir (GLE) and pibrentasvir (PIB) exhibited high virologic efficacy tolerability in patients with hepatitis C virus (HCV) infection. This study sought to confirm these findings real‐world settings, focusing on cirrhosis, history DAA failure, or HCV genotype 3 who were treated 12‐week large multicenter from Japan. Methods nationwide prospective cohort study, we analyzed background characteristics, tolerability, treatment outcome underwent GLE/PIB regimen. Results Of 1190 patients, 509 (42.8%) the regimen, remaining an 8‐week The rate sustained response (SVR) was 99.0%, comparable that adverse events observed 29.1% patients. main event pruritus, which 14.7%. Ten (2.0%) discontinued therapy during period. Conclusion well‐tolerated experience DAA, 3; SVR those DAA‐naïve, non‐cirrhotic, non‐genotype